Albelowi L, Alhazmi R, Ibrahim S
Cureus. 2025; 16(12):e75859.
PMID: 39822479
PMC: 11736671.
DOI: 10.7759/cureus.75859.
Seong S, Oh S
Ann Dermatol. 2024; 36(4):197-208.
PMID: 39082655
PMC: 11291099.
DOI: 10.5021/ad.24.038.
Madigan K, Rudnick S, Agnew M, Urooj N, Bonkovsky H
Pharmaceuticals (Basel). 2024; 17(1).
PMID: 38256864
PMC: 10819203.
DOI: 10.3390/ph17010031.
Shahbazi A, Zargar S, Aghdami N, Habibi M
Cell Tissue Bank. 2023; 25(1):143-157.
PMID: 37046149
DOI: 10.1007/s10561-023-10081-5.
Yu H, Lin X, Huang Y, Cheng H, Seifert O
Indian J Dermatol. 2021; 66(4):331-336.
PMID: 34759388
PMC: 8530050.
DOI: 10.4103/ijd.IJD_774_19.
Erythropoietic protoporphyria: time to prodrome, the warning signal to exit sun exposure without pain-a patient-reported outcome efficacy measure.
Wensink D, Langendonk J, Overbey J, Balwani M, Van Broekhoven E, Wagenmakers M
Genet Med. 2021; 23(9):1616-1623.
PMID: 33941881
DOI: 10.1038/s41436-021-01176-z.
Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide.
Arisi M, Rossi M, Rovati C, Tomasi C, Mori L, Laini L
Photochem Photobiol Sci. 2021; 20(2):315-320.
PMID: 33721252
DOI: 10.1007/s43630-021-00020-2.
2019 FDA TIDES (Peptides and Oligonucleotides) Harvest.
Al Shaer D, Al Musaimi O, Albericio F, de la Torre B
Pharmaceuticals (Basel). 2020; 13(3).
PMID: 32151051
PMC: 7151716.
DOI: 10.3390/ph13030040.
α-Melanocyte-Stimulating Hormone Attenuates Neovascularization by Inducing Nitric Oxide Deficiency via MC-Rs/PKA/NF-κB Signaling.
Weng W, Wu C, Wang F, Wu C, Ma Y, Chan H
Int J Mol Sci. 2018; 19(12).
PMID: 30513637
PMC: 6321109.
DOI: 10.3390/ijms19123823.
Novel approaches to vitiligo treatment via modulation of mTOR and NF-κB pathways in human skin melanocytes.
Wan J, Lin F, Zhang W, Xu A, DeGiorgis J, Lu H
Int J Biol Sci. 2017; 13(3):391-400.
PMID: 28367103
PMC: 5370446.
DOI: 10.7150/ijbs.17318.
Vitiligo Pathogenesis and Emerging Treatments.
Rashighi M, Harris J
Dermatol Clin. 2017; 35(2):257-265.
PMID: 28317534
PMC: 5362109.
DOI: 10.1016/j.det.2016.11.014.
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.
Minder E, Barman-Aksoezen J, Schneider-Yin X
Clin Pharmacokinet. 2017; 56(8):815-823.
PMID: 28063031
DOI: 10.1007/s40262-016-0501-5.
Advances in the management of erythropoietic protoporphyria - role of afamelanotide.
Lane A, McKay J, Bonkovsky H
Appl Clin Genet. 2016; 9:179-189.
PMID: 28003770
PMC: 5161401.
DOI: 10.2147/TACG.S122030.
[Erythropoietic protoporphyria : Clinical manifestations, diagnosis and new therapeutic possibilities].
Urbanski U, Frank J, Neumann N
Hautarzt. 2015; 67(3):211-5.
PMID: 26669872
DOI: 10.1007/s00105-015-3733-7.
Protoporphyrin IX: the Good, the Bad, and the Ugly.
Sachar M, Anderson K, Ma X
J Pharmacol Exp Ther. 2015; 356(2):267-75.
PMID: 26588930
PMC: 4727154.
DOI: 10.1124/jpet.115.228130.
Afamelanotide for Erythropoietic Protoporphyria.
Langendonk J, Balwani M, Anderson K, Bonkovsky H, Anstey A, Bissell D
N Engl J Med. 2015; 373(1):48-59.
PMID: 26132941
PMC: 4780255.
DOI: 10.1056/NEJMoa1411481.
A molecular systems approach to modelling human skin pigmentation: identifying underlying pathways and critical components.
Raghunath A, Sambarey A, Sharma N, Mahadevan U, Chandra N
BMC Res Notes. 2015; 8:170.
PMID: 25925987
PMC: 4424494.
DOI: 10.1186/s13104-015-1128-6.
A review of common tanning methods.
Garone M, Howard J, Fabrikant J
J Clin Aesthet Dermatol. 2015; 8(2):43-7.
PMID: 25741402
PMC: 4345932.
Scopoletin from Cirsium setidens Increases Melanin Synthesis via CREB Phosphorylation in B16F10 Cells.
Ahn M, Hur S, Kim E, Lee S, Shin J, Kim M
Korean J Physiol Pharmacol. 2014; 18(4):307-11.
PMID: 25177162
PMC: 4146632.
DOI: 10.4196/kjpp.2014.18.4.307.
MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.
Garcia-Borron J, Abdel-Malek Z, Jimenez-Cervantes C
Pigment Cell Melanoma Res. 2014; 27(5):699-720.
PMID: 24807163
PMC: 4150834.
DOI: 10.1111/pcmr.12257.
